Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2018
At a glance
- Drugs MVI 816 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 27 Jun 2018 Planned End Date changed from 1 Mar 2020 to 1 Apr 2020.
- 27 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2020.
- 10 Jun 2017 Biomarkers information updated